Episode 194: Cabinet Health – The Story of a Sustainable Health-tech Startup

Episode 194: Cabinet Health – The Story of a Sustainable Health-tech Startup

I sit down with Russell Gong, President and CEO of Cabinet Health, and Eric Lessard, Vice President of Pharmacy, to explore their mission to revolutionize the healthcare industry with sustainable practices.

My guests discuss the inspiration behind Cabinet Health, the significance of reducing plastic waste with their eco-friendly refillable medicine system, the startup’s success metrics, their customer engagement strategies, and the unique features of their packaging. Additionally, they share insights from their transformative experience on Shark Tank and how it helped propel their vision for a greener healthcare future.

 

Related Resources

Find out more about Cabinet Health

Watch the Cabinet Health pitch on Shark Tank.

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More